BACKGROUND: With stressors of dialysis prekidney transplantation (KT) and restoration of kidney function post-KT, it is likely that KT recipients experience a decline in functional status while on the waitlist and improvements post-KT. METHODS: We leveraged 224 832 KT recipients from the national registry (SRTR, February 1990-May 2019) with measured Karnofsky Performance Status (KPS, 0%-100%) at listing, KT admission, and post-KT. We quantified the change in KPS from listing to KT using generalized linear models. We described post-KT KPS trajectories using adjusted mixed-effects models and tested whether those trajectories differed by age, sex, race, and diabetes status using a Wald test among all KT recipients. We then quantified risk adverse post-KT outcomes (mortality and all-cause graft loss [ACGL]) by preoperative KPS and time-varying KPS. RESULTS: Mean KPS declined from listing (83.7%) to admission (78.9%) (mean = 4.76%, 95% confidence interval [CI]: -4.82, -4.70). After adjustment, mean KPS improved post-KT (slope = 0.89%/y, 95% CI: 0.87, 0.91); younger, female, non-Black, and diabetic recipients experienced greater post-KT improvements (Pinteractions < 0.001). Lower KPS (per 10% decrease) at admission was associated with greater mortality (adjusted hazard ratio [aHR] = 1.11, 95% CI: 1.10, 1.11) and ACGL (aHR = 1.08, 95% CI: 1.08, 1.09) risk. Lower post-KT KPS (per 10% decrease; time-varying) were more strongly associated with mortality (aHR = 1.93, 95% CI: 1.92, 1.94) and ACGL (aHR = 1.84, 95% CI: 1.83, 1.85). CONCLUSIONS: Functional status declines pre-KT and improves post-KT in the national registry. Despite post-KT improvements, poorer functional status at KT and post-KT are associated with greater mortality and ACGL risk. Because of its dynamic nature, clinicians should repeatedly screen for lower functional status pre-KT to refer vulnerable patients to prehabilitation in hopes of reducing risk of adverse post-KT outcomes.
BACKGROUND: With stressors of dialysis prekidney transplantation (KT) and restoration of kidney function post-KT, it is likely that KT recipients experience a decline in functional status while on the waitlist and improvements post-KT. METHODS: We leveraged 224 832 KT recipients from the national registry (SRTR, February 1990-May 2019) with measured Karnofsky Performance Status (KPS, 0%-100%) at listing, KT admission, and post-KT. We quantified the change in KPS from listing to KT using generalized linear models. We described post-KT KPS trajectories using adjusted mixed-effects models and tested whether those trajectories differed by age, sex, race, and diabetes status using a Wald test among all KT recipients. We then quantified risk adverse post-KT outcomes (mortality and all-cause graft loss [ACGL]) by preoperative KPS and time-varying KPS. RESULTS: Mean KPS declined from listing (83.7%) to admission (78.9%) (mean = 4.76%, 95% confidence interval [CI]: -4.82, -4.70). After adjustment, mean KPS improved post-KT (slope = 0.89%/y, 95% CI: 0.87, 0.91); younger, female, non-Black, and diabetic recipients experienced greater post-KT improvements (Pinteractions < 0.001). Lower KPS (per 10% decrease) at admission was associated with greater mortality (adjusted hazard ratio [aHR] = 1.11, 95% CI: 1.10, 1.11) and ACGL (aHR = 1.08, 95% CI: 1.08, 1.09) risk. Lower post-KT KPS (per 10% decrease; time-varying) were more strongly associated with mortality (aHR = 1.93, 95% CI: 1.92, 1.94) and ACGL (aHR = 1.84, 95% CI: 1.83, 1.85). CONCLUSIONS: Functional status declines pre-KT and improves post-KT in the national registry. Despite post-KT improvements, poorer functional status at KT and post-KT are associated with greater mortality and ACGL risk. Because of its dynamic nature, clinicians should repeatedly screen for lower functional status pre-KT to refer vulnerable patients to prehabilitation in hopes of reducing risk of adverse post-KT outcomes.
Authors: Natasha H Dolgin; Paulo N A Martins; Babak Movahedi; Kate L Lapane; Fred A Anderson; Adel Bozorgzadeh Journal: Clin Transplant Date: 2016-10-20 Impact factor: 2.863
Authors: Peter P Reese; Roy D Bloom; Justine Shults; Arwin Thomasson; Adam Mussell; Sylvia E Rosas; Kirsten L Johansen; Peter Abt; Matthew Levine; Arthur Caplan; Harold I Feldman; Jason Karlawish Journal: Transplantation Date: 2014-01-27 Impact factor: 4.939
Authors: Christine E Haugen; Nadia M Chu; Hao Ying; Fatima Warsame; Courtenay M Holscher; Niraj M Desai; Miranda R Jones; Silas P Norman; Daniel C Brennan; Jacqueline Garonzik-Wang; Jeremy D Walston; Adam W Bingaman; Dorry L Segev; Mara McAdams-DeMarco Journal: Clin J Am Soc Nephrol Date: 2019-03-19 Impact factor: 8.237
Authors: Mara A McAdams-DeMarco; Matthew Daubresse; Sunjae Bae; Alden L Gross; Michelle C Carlson; Dorry L Segev Journal: Clin J Am Soc Nephrol Date: 2018-08-09 Impact factor: 8.237
Authors: Alvin Thomas; Christine E Haugen; Alexandra Mountford; Fatima Warsame; Rachel Berkowitz; Sunjae Bae; Charles H Brown; Daniel C Brennan; Karin J Neufeld; Michelle C Carlson; Dorry L Segev; Mara McAdams-DeMarco Journal: J Am Soc Nephrol Date: 2018-04-23 Impact factor: 10.121
Authors: Peter P Reese; Justine Shults; Roy D Bloom; Adam Mussell; Meera N Harhay; Peter Abt; Matthew Levine; Kirsten L Johansen; Jason T Karlawish; Harold I Feldman Journal: Am J Kidney Dis Date: 2015-07-07 Impact factor: 8.860
Authors: J Kobashigawa; K Khush; M Colvin; M Acker; A Van Bakel; H Eisen; Y Naka; J Patel; D A Baran; T Daun; M Luu; M Olymbios; J Rogers; V Jeevanandam; F Esmailian; F D Pagani; B Lima; J Stehlik Journal: Am J Transplant Date: 2017-06-13 Impact factor: 8.086
Authors: Mara A McAdams-DeMarco; Elizabeth A King; Xun Luo; Christine Haugen; Sandra DiBrito; Ashton Shaffer; Lauren M Kucirka; Niraj M Desai; Nabil N Dagher; Bonnie E Lonze; Robert A Montgomery; Jeremy Walston; Dorry L Segev Journal: Ann Surg Date: 2017-12 Impact factor: 12.969
Authors: Xiaomeng Chen; Yi Liu; Valerie Thompson; Nadia M Chu; Elizabeth A King; Jeremy D Walston; Jon A Kobashigawa; Darshana M Dadhania; Dorry L Segev; Mara A McAdams-DeMarco Journal: BMC Geriatr Date: 2022-01-27 Impact factor: 3.921